For research use only. Not for therapeutic Use.
Mirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD.
| Catalog Number | I047352 |
| Purity | ≥95% |
| Reference | [1] Moore KN, et al. J Clin Oncol. 2017 Apr 1;35(10):1112-1118. |
